WUXI XDC (02268) announces happy profit forecast, with expected annual net profit increase of over 38% in 2025.

date
22:54 14/01/2026
avatar
GMT Eight
Pharmaron (02268) announces that the group expects the following financial performance for the year ending December 31, 2025: (1) Revenue: an increase of over 45% compared to the year ending December 31, 2024; (2) Gross profit: an increase of over 70% compared to the year ending December 31, 2024.
WUXI XDC (02268) announced that it expects the group to achieve the following financial performance for the year ending December 31, 2025: (1) Revenue: to increase by over 45% compared to the year ending December 31, 2024; (2) Gross profit: to increase by over 70% compared to the year ending December 31, 2024. The increase in gross profit rate is higher than the revenue growth rate, indicating effective optimization of the group's product/service profit margins and cost control capabilities; (3) Adjusted net profit before deducting interest income and expenses: to increase by over 45% compared to the year ending December 31, 2024. Excluding the impact of exchange rate fluctuations, the growth rate is expected to exceed 65%, confirming the strong profit growth momentum of the group's core operations; (4) Net profit: despite the adverse impact of exchange rate and interest rate fluctuations, to increase by over 38% compared to the year ending December 31, 2024.